Sensyne Health, the British Clinical AI technology company, has signed a £470,000 agreement with the Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The agreement with the Department of Health & Social Care follows an announcement made by Sensyne on 9th February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: “We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK’s COVID-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study.”
